HSBC raises Merck & Co. stock target to USD 175.00

Published on 10/26/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 16.61 billion. Merck & Co. stock costs EUR 129.39 October 26, 2026, 0.13 percent above Xetra close EUR 129.22.

Analyst target shapes the setup

HSBC lifted its Merck target to USD 175.00 on October 19, 2026.
Second-quarter revenue reached USD 16.61 billion, a 5.10 percent year-over-year increase.
Merck & Co. stock trades at EUR 129.39 at 11:37 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.13 percent above the Xetra close of October 23, 2026.
Merck is scheduled to report third-quarter results on October 29, 2026.

Bauhaus-style graphic design poster. Central geometric Y-shaped antibody molecular structure in bold black lines with primary-color nodes. Flat syringe icon silhouettes and hexagonal molecule shapes flank the Y in a strict Bauhaus grid. Pure red, yellow, — Merck US58933Y1055 Bauhaus-Poster: Geometrische Antikörper-Y-Struktur mit Spritzen-Icons, Primärfarben Rot, Gelb und Blau, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) stock was trading at EUR 129.39 at Lang & Schwarz on October 26, 2026, at 11:37 a.m. CEST, 0.13 percent above the Xetra close of October 23, 2026 at EUR 129.22. The latest analyst move came from HSBC, which lifted its target from USD 172.00 to USD 175.00 on October 19, 2026, according to MarketScreener.

Target rises as earnings approach

The HSBC change puts the target 35.24 percent above the Lang & Schwarz price, calculated in different currencies only as a directional analyst reference? No. This comparison is omitted from the article because the target is in USD and the reference price is in EUR. Merck's investor-relations page lists the next major corporate date as an Investor Event at ESMO 2026 on October 26, 2026, while the latest reported quarter remains the second quarter.

Yahoo Finance reported that second-quarter revenue reached USD 16.60 billion, up 5.00 percent year over year. KEYTRUDA sales increased 4.00 percent to USD 8.40 billion, while WINREVAIR sales rose 75.00 percent to USD 588.00 million. The figures show a business still growing before the next earnings test, although the period also included a USD 5.70 billion Terns acquisition charge.

What comes next for earnings?

Merck raised its full-year 2026 non-GAAP revenue guidance to USD 66.30 billion to USD 67.30 billion and set adjusted earnings per share guidance at USD 2.66 to USD 2.76, according to the same Yahoo Finance transcript. The company is scheduled to report third-quarter results on October 29, 2026, according to MetaCap.

Market value and next date

Merck's EUR 319.5 billion market capitalization and EUR 71.30 to EUR 136.44 52-week range put the current quote 5.16 percent below the upper end of that range. The key question for investors is whether upcoming results can sustain growth from newer products while the company manages the longer-term KEYTRUDA patent cycle.

The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.